CORT.US Corcept Therapeutics Incorporated

Healthcare Pharmaceuticals USA Stocks
72.94 USD
Close of Nov 13, 2026
28.66 126.38
Market cap
USD 7.98B
P/E
55.3x
P/B
9.55x
ROE
22.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CORT.US undervalued?

Graham number

The Graham number of Corcept Therapeutics Incorporated cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Corcept Therapeutics Incorporated fundamental analysis

No fundamental analysis for Corcept Therapeutics Incorporated yet.

Corcept Therapeutics Incorporated stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not ca…

Full company profile